F.1-22/Adv/FEDSD/2019

Field Epidemiology & Disease Surveillance Division Ministry of National Health Services, Regulations & Coordination

Ph: (92-051) 9255238 Fax: (92-051) 9255099

National Focal Point for International Health Regulations

Advisory for the Prevention and Control of Chikungunya Viral Infection

Purpose:

Following an outbreak of Chikungunya in Karachi in 2017 and subsequently detection of travel associated cases in different parts of the country, the disease is now endemic in many parts of the country like Dengue Fever. Keeping in view the hyper active season of mosquitoes, and previous seasonal trends of the disease, it is imperative to undertake preventive measures while staying vigilant to pick suspected cases, confirming the disease, and taking steps to interrupt further transmission.

The objective of this advisory is to sensitize health care authorities to further strengthen and improve the level of preparedness in prevention and control of Acute Febrile Viral Illness (suspected Chikungunya) Infection.

Background:

Chikungunya is a viral disease caused by Chikungunya Virus (CHKV) and transmitted by Aedes mosquitoes to humans. The word 'chikungunya' means 'that which bends up', an allusion to the posture of the suffering patients. Chikungunya occurs in tropical countries and has been reported from Africa, South Asia and South-East Asia. The disease shares some clinical signs with dengue, and can be misdiagnosed in areas where dengue is common. However, the CHKV infections are rarely fatal without any significant hemorrhagic manifestations. The proximity of mosquito breeding sites to human habitation is a significant risk factor. The viruses can circulate in same area with dengue and cause occasional co-infections in the same patient.

Incubation period:

4 to 8 days (can be 2- 12 days). Viraemia persists for 5 – 7 days from the onset of symptoms.

Transmission:

- Chikungunya is spread by the bite of Aedes mosquitoes, primarily Aedes aegypti and also Aedes albopictus. These mosquitoes are active during the day. Both species are found biting outdoors, but Aedes aegypti will also readily feed indoors.
- Mostly the transmission usually occurs during or just after the hot rainy season.
- Mother-to-child transmission has also been reported in women who developed the disease
 within the final week prior to delivery. There are rare reports of spontaneous abortions
 following maternal chikungunya virus infection. There is no evidence that the virus is
 transmitted through breast milk.

Clinical presentation:

 The disease is characterized by a sudden onset of fever, chills, headache, myalgia, nausea, photophobia, incapacitating joint pain and petechial or maculopapular rash. Once a person has recovered from chikungunya infection, he or she is likely to have a life-long immunity against subsequent chikungunya virus infections. Clinical presentation of Chikungunya usually follows 3 phases as follows:

Contd on P/2

- Acute phase: The disease is characterized by severe, sometimes persistent joint pains. The
 areas around the joints become swollen and painful to touch. This acute phase is severe and
 incapacitating and lasts 3–10 days. A patient may be unable to move or walk at this time.
- 2. **Sub-acute phase:** Skin rashes occur in 40–50% of patients, usually appearing between 2 and 5 days after the onset of fever. Unlike the small, dot-like rash seen in dengue fever, the chikungunya rashes are big and flat (maculopapular rash).
- 3. **Chronic phase:** The chronic/ convalescent phase can last from weeks to months with accompanying joint pain and rheumatism. Rarely the effects can last for years.

General complications are rare and include myocarditis, hepatitis and ocular and neurological disorders. Risk factors for more severe disease are: last weeks of pregnancy for the neonates exposed intrapartum, older age (> 65 years) and co-morbidities. In the elderly, arthralgia can evolve to a chronic rheumatoid arthritis syndrome. Meningoencephalitis affects primarily neonates. **Diagnostics:**

- Chikungunya virus can be identified using Real-time polymerase chain reaction (RT-PCR)/ nucleic acid/genomic amplification techniques or viral isolation during the first week of illness.
- Serological diagnosis can be performed by detection of specific IgM antibodies in serum specimen from day 4–5 after the onset of illness. Specific IgM can persist for many months, in particular in patients with long-lasting arthralgia.

Treatment:

There is no specific treatment for the disease and mainly relies on the management of symptoms. Neither any vaccine nor any anti-viral are available for prevention and treatment.

The following measures are recommended:

- Get plenty of rest
- Drink fluids to prevent dehydration
- Symptomatic treatment is advised preferably with Acetaminophen.
- Do not take aspirin and other non-steroidal anti-inflammatory drugs (NSAIDS) like ibuprofen, naproxen etc.
- If you are taking medicine for another medical condition, talk to your healthcare provider before taking additional medication for CHKV infections.

Prevention & Control:

- No vaccine or prophylactic drug is available.
- Integrated vector management aiming to reduce mosquito vector density in a sustainable manner is of primary importance.
- Inter-sectoral collaboration and efficient public communication strategy to ensure community participation are required for sustainable vector control program.
- Activities supporting the reduction of mosquito breeding sites in outdoor/indoor areas by draining or discarding sources of standing water at the community level include:
 - Removal of all open containers with stagnant water in and surrounding houses on a regular basis (flower plates and pots, used tyres, tree-holes and rock pools), or, if that is not possible, treatment with larvicides),
 - Tight coverage of water containers, barrels, wells and water storage tanks,
 - Wide use of window/door screens by the population.
- Measures aiming to control larvae and adult mosquito vector population can be applied in an outbreak situation.
- In affected outbreak areas, elimination of adult mosquitoes through aerial spraying with insecticides can be considered.

Infection control, personal protection and prevention:

 Prevention is also based on protection against mosquito bites. Aedes mosquitoes have diurnal biting activities in both indoor and outdoor environments. Therefore personal protection measures should be applied all day long and especially during the hours of highest mosquito activity (mid-morning, late afternoon to twilight).

 Using repellents and wearing long-sleeved shirts and long pants, using long-lasting insecticidal treated mosquito bed nets, and removing mosquito breeding sites in close

outdoor/indoor premises

Surveillance for human infections:

Kindly evaluate the suspected case(s) or clustering of suspected cases. This may please communicated to the districts health officials and other stakeholders for information and action. Prepare a line-list for all the suspected cases with information (demographic, clinical & risk factor) and share with DSRU at provincial DGHS Office and NIH. The Field Epidemiology and Disease Surveillance Division (FE&DSD), NIH may be contacted for technical assistance on Tel: 051-9255237 and Fax No. 051-9255575.